Cellular and molecular pathobiology of heart failure with preserved ejection fraction

S Mishra, DA Kass - Nature Reviews Cardiology, 2021 - nature.com
Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

Mitochondrial function as a therapeutic target in heart failure

DA Brown, JB Perry, ME Allen, HN Sabbah… - Nature Reviews …, 2017 - nature.com
Heart failure is a pressing worldwide public-health problem with millions of patients having
worsening heart failure. Despite all the available therapies, the condition carries a very poor …

Nitrosative stress drives heart failure with preserved ejection fraction

GG Schiattarella, F Altamirano, D Tong, KM French… - Nature, 2019 - nature.com
Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with high
morbidity and mortality for which there are no evidence-based therapies. Here we report that …

Treatments targeting inotropy: a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European …

C Maack, T Eschenhagen, N Hamdani… - European heart …, 2019 - academic.oup.com
Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

Biological phenotypes of heart failure with preserved ejection fraction

GA Lewis, EB Schelbert, SG Williams… - Journal of the American …, 2017 - jacc.org
Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological
mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and …

The control of diastolic calcium in the heart: basic mechanisms and functional implications

DA Eisner, JL Caldwell, AW Trafford… - Circulation …, 2020 - Am Heart Assoc
Normal cardiac function requires that intracellular Ca2+ concentration be reduced to low
levels in diastole so that the ventricle can relax and refill with blood. Heart failure is often …

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?

M Trum, J Riechel, S Wagner - International Journal of Molecular …, 2021 - mdpi.com
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …

Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications

AS Manolis, AA Manolis, TA Manolis… - Medicinal Research …, 2021 - Wiley Online Library
Mitochondria provide energy to the cell during aerobic respiration by supplying~ 95% of the
adenosine triphosphate (ATP) molecules via oxidative phosphorylation. These organelles …

RyR2 and calcium release in heart failure

JP Benitah, R Perrier, JJ Mercadier, L Pereira… - Frontiers in …, 2021 - frontiersin.org
Heart Failure (HF) is defined as the inability of the heart to efficiently pump out enough blood
to maintain the body's needs, first at exercise and then also at rest. Alterations in Ca2+ …

ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology …

KE Odening, AM Gomez, D Dobrev, L Fabritz… - EP …, 2021 - academic.oup.com
Cardiac arrhythmias are a major cause of death and disability. A large number of
experimental cell and animal models have been developed to study arrhythmogenic …